Added to YB: 2026-09-16
Pitch date: 2026-09-10
AZN [neutral]
AstraZeneca PLC
+2.91%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
Market Cap
GBP 245.6B
Pitch Price
GBP 118.10
Price Target
N/A
Dividend
2.04%
EV/EBITDA
13.45
P/E
23.70
EV/Sales
4.45
Sector
Pharmaceuticals
Category
growth
AstraZeneca (AZN UK): Tozorakimab opens a large COPD opportunity across a broad patient population
AZN (update): AstraZeneca’s tozorakimab could anchor a new respiratory franchise with company-estimated peak sales above $5bn after Phase III trials reduced moderate or severe COPD exacerbations by 29-34% across a broad eosinophil spectrum. US Priority Review and a Q1 2027 FDA decision provide a defined path forward, while the key unresolved issue is a cardiovascular-event imbalance that requires longer follow-up despite no clear evidence of a drug-related safety problem.
Read full article (2 min)